Please login to the form below

Not currently logged in
Email:
Password:

fezolinetant

This page shows the latest fezolinetant news and features for those working in and with pharma, biotech and healthcare.

Bayer moves vilaprisan into phase III trials for uterine fibroids

Bayer moves vilaprisan into phase III trials for uterine fibroids

have acquired Ogeda and its phase IIa candidate Fezolinetant.

Latest news

  • Astellas agrees €800m deal to buy Belgian biotech Ogeda Astellas agrees €800m deal to buy Belgian biotech Ogeda

    Astellas is paying 500m upfront and up to 300m extra in clinical and regulatory milestones for Ogeda (formerly known as Euroscreen) and its lead candidate fezolinetant, which has been shown in ... In a phase IIa trial reported in January, fezolinetant

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    The lead product is a NK3 receptor antagonist (fezolinetant) for treatment of menopause-related vasomotor symptoms (hot flashes).  Fezolinetant successfully completed a phase 2a study in January in 80 menopausal ... regulatory outcomes of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....